Therefore, although our data suggest that inhibition of myostatin/activin A signalling would provide a symptomatic treatment rather than one targeting the underlying pathogenic basis of the disease, this may have considerable impact on the overall quality of life for HD patients in terms of increased mobility and a reduction in falls, as well as the cognitive and mood benefits that could arise through an increased exercise capacity50,51. Here, MSTN is linked to Huntington disease.